Serum tumour markers in patients with chronic kidney disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 67, Issue 6, 2007, Pages 661-667

  Xiaofang, Y ^a   Yue, Z ^a   Xialian, X ^a   Zhibin, Y ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chronic renal failure; Creatinine clearance rate; Diagnostic value; Hemodialysis; Serum concentration

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER; ANTIGEN CYFRA21.1; KERATIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DIAGNOSTIC VALUE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; CHRONIC KIDNEY FAILURE; GLOMERULUS FILTRATION RATE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; STATISTICS;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CA-15-3 ANTIGEN; CA-19-9 ANTIGEN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KERATINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38749150398     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701282326     Document Type: Article

References (25)

1. Berzinec P, Zuffova H, Letkovicova M, Arpasova M. Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer - comparison with CEA. Neoplasma 1996;43:159-61.
2. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients. Cancer 1996;78:736-40.
3. Diez M, Torres A, Maestro ML, Ortega MD, Gomez A, Pollan M, et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 1996;73:1248-54.
4. Kiss B, Magyarlaki T, Buzogany I, Fazekas A, Sukosd F, Nagy J. Paraneoplastic nephropathy associated with adult renal carcinoma. Orvosi Hetilap 1999;10,140:75-80.
5. Kumar SK, Sohal PM, Kohli HS, Sud K, Gupta KL, Joshi K, et al. Acute renal failure due to cast nephropathy in nonsecretory myeloma: a case report and review of the literature. Int Urol Nephrol 2005;37:351-3.
6. Chen KJ, Jan YJ, Chen CH, Cheng CH, Wu MJ, Shu KH. Multiple myeloma-associated cast nephropathy with crystal structure: case report and review of the literature. Nephrology 2005;10:594-6.
7. Dogan E, Izmirli M, Ceylan K, Erkoc R, Sayarlioglu H, Begenik H, et al. Incidence of renal insufficiency in cancer patients. Advances in Therapy 2005;22:357-62.
8. Eneman JD, Philips GK. Cancer management in patients with end-stage renal disease. Oncology (Huntington) 2005;19:1199-212.
9. Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol 2005;16:151-61.
10. Nomura F, Koyama A, Ishijima M, Takano S, Narita M, Nakai T. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure. Oncol Rep 1998;5:389-92.
11. Filella X, Cases A, Molina R, Jo J, Bedini JL, Revert L, et al. Tumor markers in patients with chronic renal failure. Int J Biol Markers 1990;5:85-8.
12. Arik N, Adam B, Akpolat T, Hasil K, Tabak S. Serum tumour markers in renal failure. Int Urol Nephrol 1996;28:601-4.
13. Lehtovirta P, Apter D, Stenman UH. Serum CA 125 levels during the menstrual cycle. Br J Obstet Gynaecol 1990;97:930-3.
14. Kan YY, Yeh SH, Ng HT, Lou CM. Effect of menstruation on serum CA125 levels. Asia-Oceania J Obst Gynaecol 1992;18:339-43.
15. Harper L, McIntyre CW, MacDougall IC, Meyer P, Raine AE, Baker LR. Prostate-specific antigen levels in patients receiving long-term dialysis. Br J Urol 1995;76:482-3.
16. Sumura M, Yokogi H, Beppu M, Honda H. Diagnostic value of serum prostate-specific antigen in hemodialysis patients. Int J Urol 2003;10:247-50.
17. Bruun L, Bjork T, Lilja H, Becker C, Gustafsson O, Christensson A. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. NDT 2003;18:598-603.
18. Sasagawa I, Kubota Y, Hayami S, Adachi M, Nakada T, Miura H, et al. Serum levels of total and free prostate specific antigen in men on hemodialysis. J Urol 1998;160:83-5.
19. Danisman A, Kilic S, Kukul E, Yakupoglu G, Guntekin E, Baykara M, et al. Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen? Eur Urol 2000;37:579-81.
20. Docci D, Turci F, Pistocchi E. High levels of carcinoembryonic antigen (CEA) in the serum of uremic patients under hemodialysis treatment. Quad Sclavo Diagnostica 1984;20:435-9.
21. Ammon A, Eiffert H, Weber MH, Rummel J, Niemann J. Tumor markers in dialysis-dependent renal failure. A comparison of the mucin-like carcinoma antigen, CA15-3, CA125, CA19-9 and CEA antigens. Onkologie 1988;11:260-2.
22. Lye WC, Tambyah P, Leong SO, Lee EJ. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Peritoneal Dialysis 1994;10:109-11.
23. Zeferos N, Digenis GE, Christophoraki M, Alexopoulos I, Kostakis A, Gyftaki H, et al. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron 1991;59:618-20.
24. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183-6.
25. Nakahama H, Tanaka Y, Fujita Y, Fujii M, Sugita M. Tumor markers of lung cancer are elevated in chronic renal failure patients. Respirology 1998;3:207-10.